MS170

For research use only. Not for therapeutic Use.

  • CAT Number: I045155
  • CAS Number: 2376136-61-5
  • Molecular Formula: C45H56ClN9O7
  • Molecular Weight: 870.44
  • Purity: ≥95%
Inquiry Now

MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total AKT (T-AKT) with the DC50 value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with Kds of 1.3 nM, 77 nM, and 6.5 nM, respectively[1].
Cereblon (CRBN)-recruiting degrader MS170 is an effective AKT degrader without a ″hook effect″. MS170 selectively induces robust AKT protein degradation, inhibits downstream signaling, and suppresses cancer cell proliferation. MS170 concentration- and time-dependently induces AKT degradation through the ubiquitin-proteasome system (UPS)[1].
MS170 (10 nM-10 μM) effectively inhibits the proliferation in multiple cancer cell lines[1].
MS170 (1 nM-10 μM) concentration-dependently depletes cellular total AKT (T-AKT) with the DC50 value of 32±18 nM[1].
MS170 (a single intraperitoneal injection at a dose of 50 mg/kg) is bioavailable in mice via IP injection[1].


Catalog Number I045155
CAS Number 2376136-61-5
Synonyms

3-[[(2S)-2-(4-chlorophenyl)-3-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-oxopropyl]amino]-N-[8-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]octyl]propanamide

Molecular Formula C45H56ClN9O7
Purity ≥95%
InChI InChI=1S/C45H56ClN9O7/c1-28-25-35(56)40-38(28)41(51-27-50-40)53-21-23-54(24-22-53)43(60)32(29-11-13-30(46)14-12-29)26-47-20-17-36(57)49-19-7-5-3-2-4-6-18-48-33-10-8-9-31-39(33)45(62)55(44(31)61)34-15-16-37(58)52-42(34)59/h8-14,27-28,32,34-35,47-48,56H,2-7,15-26H2,1H3,(H,49,57)(H,52,58,59)/t28-,32-,34?,35-/m1/s1
InChIKey QMLFGZYEQAMKRK-SCQVZNLVSA-N
SMILES CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNCCC(=O)NCCCCCCCCNC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)C7=CC=C(C=C7)Cl)O
Reference

[1]. Yu X, et al. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. J Med Chem. 2021;64(24):18054-18081.
 [Content Brief]

Request a Quote